{"url_path":"/sec/clov/8-k/2026-05-18/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1801170/0001801170-26-000128-index.html","accession_number":"0001801170-26-000128","cik":"0001801170","ticker":"CLOV","issuer_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","edgar_url":"https://www.sec.gov/Archives/edgar/data/1801170/0001801170-26-000128-index.html","primary_entity_key":"0001801170","primary_entity_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE"},"word_count":384,"has_tables":true,"body_markdown":"clov-20260518\nFALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702026-05-182026-05-18\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\nFORM 8-K\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): May 18, 2026\n\nCLOVER HEALTH INVESTMENTS, CORP.\n\n(Exact name of Registrant as Specified in Its Charter)\n\nDelaware\n001-3925298-1515192\n\n(State or Other Jurisdiction\n(Commission File Number)\n(IRS Employer\n\nof Incorporation)\n\nIdentification No.)\n\nAddress Not Applicable(1)\n\nAddress Not Applicable(1)\n\n(Address of Principal Executive Offices)(Zip Code)\n\nNot Applicable(1)\n\n(Registrant’s Telephone Number, Including Area Code)\n\nNot Applicable\n\n(Former Name or Former Address, if Changed Since Last Report)\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTrading\n\nTitle of each class\n\nSymbol(s)\nName of each exchange on which registered\n\nClass A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801."}